These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21073988)

  • 1. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK.
    Siddiqui MR; Gay N; Edmunds WJ; Ramsay M
    Vaccine; 2011 Jan; 29(3):466-75. PubMed ID: 21073988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales.
    Mangtani P; Hall AJ; Normand CE
    J Epidemiol Community Health; 1995 Jun; 49(3):238-44. PubMed ID: 7629457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.
    Bloom BS; Hillman AL; Fendrick AM; Schwartz JS
    Ann Intern Med; 1993 Feb; 118(4):298-306. PubMed ID: 8420448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
    Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
    JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies.
    Edmunds WJ
    Commun Dis Public Health; 1998 Dec; 1(4):221-8. PubMed ID: 9854877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness.
    Harris A; Yong K; Kermode M
    Aust N Z J Public Health; 2001 Jun; 25(3):222-9. PubMed ID: 11494989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of universal vaccination against hepatitis B virus.
    Fenn P; Gray A; McGuire A
    J Infect; 1996 May; 32(3):197-204. PubMed ID: 8793708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The use of decision making analysis for evaluating hepatitis B inoculation strategy].
    Zhuang GH; Xu HW
    Zhonghua Yu Fang Yi Xue Za Zhi; 1993 Mar; 27(2):69-73. PubMed ID: 8354107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
    Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.
    Boccalini S; Taddei C; Ceccherini V; Bechini A; Levi M; Bartolozzi D; Bonanni P
    Hum Vaccin Immunother; 2013 May; 9(5):1119-28. PubMed ID: 23376840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model based analysis of hepatitis B vaccination strategies in the Netherlands.
    Kretzschmar M; Mangen MJ; van de Laar M; de Wit A
    Vaccine; 2009 Feb; 27(8):1254-60. PubMed ID: 19118594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic evaluation of various hepatitis B vaccination Strategies in Switzerland].
    Zurn P; Danthine JP
    Soz Praventivmed; 1998; 43 Suppl 1():S61-4, S134-7. PubMed ID: 9833269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.
    Holliday SM; Faulds D
    Pharmacoeconomics; 1994 Feb; 5(2):141-71. PubMed ID: 10146907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term efficacy of infant hepatitis B immunization program].
    Gong J; Li RC; Yang JY; Li YP; Chen XR; Xu ZY; Liu CB; Cao HL; Zhao K; Ni DM
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):203-5. PubMed ID: 12716514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
    Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
    Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
    Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
    Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.